NYSE:RBOT Vicarious Surgical Q1 2024 Earnings Report $8.37 +0.10 (+1.26%) Closing price 03:59 PM EasternExtended Trading$8.44 +0.07 (+0.79%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Vicarious Surgical EPS ResultsActual EPS-$2.70Consensus EPS -$3.00Beat/MissBeat by +$0.30One Year Ago EPSN/AVicarious Surgical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVicarious Surgical Announcement DetailsQuarterQ1 2024Date4/29/2024TimeN/AConference Call DateMonday, April 29, 2024Conference Call Time4:30PM ETUpcoming EarningsVicarious Surgical's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Vicarious Surgical Q1 2024 Earnings Call TranscriptProvided by QuartrApril 29, 2024 ShareLink copied to clipboard.There are 8 speakers on the call. Operator00:00:00Hello, and welcome to Vicarious Surgical's 2024 First Quarter Earnings Call. My name is Elliot, and I'll be coordinating your call today. I would now like to hand over to Caitlin Brosco, Head of Investor Relations. Operator00:00:18The floor is yours. Please go ahead. Speaker 100:00:21Thanks, Elliot, and thank you all for joining. With me today for prepared remarks are Adam Sacks, Co Founder and Chief Executive Officer and Bill Kelly, Chief Financial Officer. Later, Randy Clark, our new company President, will join for the Q and A portion of this call. Today after market closed, Bakery Surgical released financial results for the 3 months ended March 31, 2024. A copy of this press release is available on the company website. Speaker 100:00:48Before we begin, I'd like to remind you that management will make statements during this call that include forward looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward looking statements. All forward looking statements, including without limitation, those relating to obtaining approval for the Vicari Surgical System and timing for any such approval, our operating trends and future financial performance, expense management, market opportunity and commercialization are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that would cause actual results or events to materially differ from those anticipated or implied by these forward looking statements. Accordingly, you should not place any undue reliance on these statements. Speaker 100:01:44For a list and description of the risks and uncertainties associated with the business, please refer to the risk factors set forth in our Securities and Exchange Commission filings, including our most recent Form 10 ks and Form 10 Q. This conference call contains time sensitive information and is accurate only as of this live broadcast today, April 29, 2024. Vicarious Surgical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward looking statements, whether because of new information, future events or otherwise. Now, I'll hand the call over to Adam for prepared remarks. Speaker 200:02:22Thanks, Kate, and thank you, everyone, for joining us. I'm proud to report a strong start to the year as we advance our mission to improve lives by transforming surgical robotics. In the Q1, we made meaningful progress toward the finalization of our B1.0 system. The collective efforts of our development team culminated in the completion of our spring cadaver lab at the end of March. This lab marks the first use of our integrated D1.0 system in a catabaric procedural setting with the primary goal of validating the capabilities and potential of the new systems feature set. Speaker 200:02:58I'm pleased to share that the lab proceeded as we had anticipated, verifying several advancements in development and yielding valuable insights across the system. During the lab, our V1.0 system showcased the tremendous potential inherent in our novel platform, underpinned by the new fortified software, electronic and mechanical architecture and supported by enhanced instrumentation and visualization technology. The V1.0 system exhibited the dynamic motion capabilities of our patient cart, facilitated maneuverability within the abdominal cavity and enabled 360 degree visualization and access to targeted surgical sites. We highlighted many of these specific V1 point development goals in our remarks last year, and I'm happy to report the success of our team's diligent efforts since. As anticipated, in addition to our development success, the lab offers insight into the additional refinements required for our final system. Speaker 200:04:00Over the next few quarters, our team will focus on leveraging these insights to fine tune the V1.0 system in preparation for formal verification and validation against the broader landscape for surgical robotics to remind against the broader landscape for surgical robotics to remind our stakeholders why we believe our offering is poised to take a disproportionate share of this market over time. Even with considerable progress over the past few decades, the field of surgical robotics is still in its infancy. Despite substantial growth and various new market entrants, around 96% of the estimated $150,000,000,000 market opportunity remains white space. Recent strategic activity in the space continues to strongly support this notion that robotics is the future of surgery. And while existing robotic technology has notably augmented surgeons' capabilities, these multi port systems have amplified costs for the hospital system without addressing the technology's fundamental dexterity and range of motion constrain surgeons to utilizing wrist on a stick instrument that necessitate multiple incisions to the patient and require cumbersome instrument triangulation by the surgeon. Speaker 200:05:26This approach introduces complexity both during the procedure and in preoperative steps contributing to the steep learning curve for new users and the low 4% adoption rate for surgical robotics today. Vicarious Surgical was founded on the recognition of these limitations of multi port surgical robots. Instead of building off legacy robotic technology, we reimagined surgical robotics from the ground up. Core to our reimagined architecture is our proprietary decoupled actuator technology, which prevents the force buildup in the joints of each instrument arm, significantly enhancing the dexterity and range of motion of our system and thereby eliminating the need for multiple incisions required for instrument triangulation. Through a single 18 millimeter incision, our system is designed to achieve full intra abdominal access with high force exertion for our targeted surgical indication. Speaker 200:06:25We believe this streamlined approach will enhance procedural efficiency and remove the training demand on new surgeons for every procedure. With today's offerings predominantly limited to multi port wrist on a stick technology, we along with our hospital system partners see this as a distinct clinical and commercial advantage. We are confident that our technology's unique capabilities will establish a lasting competitive edge for us in the robotic assisted surgery market. And with the completion of our spring cadaver lab, we are excited to have taken another step towards finalizing our differentiated system. With that, I will turn it over to Bill to review our financial performance. Speaker 300:07:09Thank you, Adam. As expected, our 2023 initiatives streamline resources, optimize spending and restructure the company for maximum efficiency are yielding a benefit to our 2024 expense profile. As a result, total operating expenses for the Q1 of 2024 were $16,100,000 28% decrease compared to $22,300,000 in the Q1 of last year. R and D expenses for the Q1 of 2024 were $10,000,000 compared to $13,400,000 in the Q1 of 2023. General and administrative expenses for the Q1 of 2024 were $5,000,000 down from $7,000,000 in the Q1 of 2023. Speaker 300:07:56In Q1 2024, sales and marketing expenses were $1,100,000 versus $2,000,000 in the Q1 of 2023. Again, the year over year reduction in operating expenses reflects the diligent efforts made throughout last year to optimize our burn and prioritize capital efficiency. Continuing on, adjusted net loss for the first quarter 2024 was $15,100,000 equating to a net loss of $0.09 per share as compared to an adjusted net loss of $20,800,000 or $0.17 per share in the Q1 of 2023. GAAP net loss for the Q1 of 2024 was $17,000,000 equating to a net loss of $0.10 per share, and this compares to a net loss of $26,900,000 or $0.21 per share in the Q1 of 2023. For a reconciliation of all non GAAP measures to GAAP, please review our earnings press release. Speaker 300:09:00We ended the Q1 of this year with approximately $84,000,000 of cash, cash equivalents and short term investments on our balance sheet. This represents a Q1 cash burn rate of approximately $14,000,000 Note that while Q1 cash burn was slightly elevated as a result of a few seasonally timed payments, we continue to expect full year 2024 cash burn to be approximately $50,000,000 and remain committed to disciplined capital allocation. 2024 is off to a strong start and our team is executing with the urgency and discipline needed to achieve our development timelines, including the completion of the V1.0 system build and integration this fall. We look forward to updating you as we progress with our business initiatives in the coming quarters. And with that, I'll turn the call back to Adam for closing remarks. Speaker 300:09:53Adam? Speaker 200:09:53Thank you, Bill. I'd like to close by reemphasizing the way in which we as a company have differentiated ourselves within the broader robotics market. While many surgical robotics companies continue to iterate on legacy platforms, we are taking a new path forward. While this approach takes careful time and consideration, we remain steadfast in the value of our unique technology. I'd like to thank all of our stakeholders, particularly our employees for their continued support of our mission and vision. Speaker 200:10:29Elliot, we're now happy to take any questions. Operator00:10:33Thank First question comes from Ryan Zimmerman with BTIG. Your line is open. Please go ahead. Speaker 400:10:55Thanks. Thanks for taking my questions. Good afternoon. Just maybe a few for me. Your R and D expenses came in a little higher, SG and A was certainly lower than I think we expected. Speaker 400:11:08But overall, really good expense management this quarter. Just kind of help us understand kind of how you're balancing the needs on kind of both sides of that P and L as you think about your progress and kind of what you have planned for the balance of this year? Speaker 300:11:24Great question. Obviously, as we've made a number of cost reductions year over year, the focus has really been on building a quality robot and getting it to market as fast as possible and such really where we try and draw the line there to focus and prioritize spending there. As noted in the call, our burn rate was probably a little bit higher than otherwise the run rate would be. That was really due to the seasonality of certain spending. As you can imagine, certain material expenses and things like that, they happen in one period versus another. Speaker 300:11:56That's why you're seeing that. But we still remain committed to $50,000,000 cash burn for the year. Speaker 400:12:03Okay. And then correct me if I'm wrong here, Adam, but the V1.0 wraps up in the fall of this year. Talk to us about kind of next steps from there, how that dovetails into potentially the establishment of a clinical trial, I think slated for maybe mid to late 2025, if I'm not mistaken, and kind of what you need to do once we get all the design and testing done for V1.0? Speaker 200:12:37Yes. I think that's a really important question. So as we finalize our V1.0 system and go into more sort of preliminary verification and validation testing, We're going to then roll that into all of the formal testing that's required. As I'm sure you'll recall, we're focused primarily on outside the U. S. Speaker 200:12:58Data collection in our clinical trial. And one of the advantages of that is in the verification and validation process, we need to do primarily the all of the essential performance and safety testing rather than all verification and validation testing. So once essential performance and safety testing is complete for our system, we'll then be able to start up our clinical trial in 2025. Speaker 400:13:27Thank you. Operator00:13:32We now turn to Adam Maeder with Piper Sandler. Your line is open. Please go ahead. Speaker 500:13:38Hi, Adam, Bill, Randy. Thank you for taking the questions and congrats on the progress. I wanted to start with the spring cadaver lab experience and just ask a little bit more color there. So I guess the first question would be multipart here. How many cadavers were performed? Speaker 500:13:57Who is doing the procedure? Was it surgeons that you guys partner with, talk about kind of setting a care. And then just bigger picture, maybe just what were the learnings from the Spring Cadaver lab? What went better than planned? And what were some of the challenges, if any, that may have arisen? Speaker 500:14:18And then I had a follow-up. Thanks. Speaker 200:14:22Yes. Super fair question. So overall, it was the very first cadaver that we performed. This was a single cadaver and will be the first of a number that we do over the course of this year. Overall, the procedure was designed to really test out the core functionality of our system and burn down and evaluate any potential issues and risks with it as early as possible, which is one of the reasons that we did it frankly on the earlier side of the spring. Speaker 200:14:59It was done by internal surgeons and surgeon partners and with a collaboration between 2 physicians. And overall, there were a number of things across frankly each subsystem that came up that we needed to focus on revising over the next 2 to 3 quarters. And that is why we've scheduled in this time over the next couple of quarters to make those revisions before we actually lock our V1.0 system. Speaker 500:15:35Yes. That's good color, Adam. And sorry to press here a little bit, but just to the extent that you're willing to share, I think you called it additional refinements in the prepared remarks to the final system. What are some of those things that you guys need to kind of smooth out before you go into final system integration in the fall? Speaker 200:16:02Yes. I'll give you a few examples of a few different things. So within the software, there were a handful of bugs that we encountered, including one on firmware within the arms and the sensing of the arms that caused some challenges along the way. That one has actually already been resolved. A few small things between interaction between the lubrication of the trocar seal and the arm itself and the sensing of the arm. Speaker 200:16:35Just to name, I'd say 2 out of frankly a decent handful of similar things. So either one of the 2 of those are fairly easy to resolve. It's just that there are a number that we need to tackle and that's why we want to give ourselves a couple of quarters to do that and to really heavily test out the implementation of each solution. Speaker 500:17:02Yes. That makes sense to me. Thank you for that. And then just one last one, if I may. Maybe for Randy, and congratulations on the new role, by the way. Speaker 500:17:12I wanted to ask, you've been in the seat now for a few months. Maybe just talk about some of the early impressions from your vantage point of the company and the technology and how will you look to put your fingerprints on the broader organization going forward? Thanks again for taking the questions. Speaker 600:17:31Yes. No, I appreciate the new person question, Adam. So, as you mentioned, since joining at the end of January, I've really just been fully immersing myself into the intricacies of our business and really trying to familiarize myself with each team and taking deep dives into all aspects of our operations as you can imagine. And I can tell you, it's been an incredibly exciting journey so far, especially where you're going with Adam. I had the privilege of observing the team's unwavering dedication and hard work and commitment that led up to our spring Kadara lab. Speaker 600:18:07And that's one of my first takeaways that I want to double down on is just the talent that we have here at Vicarious Surgical is absolutely incredible, let alone the work ethic and commitments from the teams to really drive towards our mission. And I'm just focusing right now and being very committed to disciplined execution of our current objectives and consistently achieving our milestones. That's going to be key to ensuring our success in the long run. Speaker 500:18:38Thank Operator00:18:41you. We now turn to Josh Jennings with TD Cowen. Your line is open. Please go ahead. Speaker 700:18:54Hi, good afternoon. Thanks a lot for taking the questions. Wanted to just get an update on the plans for the OUS clinical trial to support the de novo submission. Any I know it's only been 2 months since the last call and the last update and less than that since our healthcare conference, but any further communications with the FDA on that trial design? And just I guess the second part of the question is thinking about international sites and how do you go about I know we're not till next year, but how do you go about establishing those relationships or maybe they're already in hand in terms of finding investigator sites and finding the right ones and developing those surgeon relationships or center relationships with Vicarious? Speaker 200:19:42Yes. Thanks, Josh. And 2 great questions there. So I'll start with the FDA side. So nothing that we have to share on that front directly. Speaker 200:19:52But what I will say is, as we're seeing the broader robotics base continue to develop, we are seeing other filings and frankly other approvals come through, many of which are occurring with entirely outside the U. S. Data as well as with about 30 patients each in each trial. So this is further confirming that unsurprisingly the guidance and support that the FDA is giving to us is being given in exactly the same way to the other new entrants in the space and they are following through on their commitments there. So that is very reassuring for us to see. Speaker 200:20:36As far as specific site selection and country selection, we are in conversations with a number of different locations. We do have time, but we are well on the way to working through this already. And one of the goals here is to maintain optionality for as long as we can. We actually view that as a distinct advantage, especially when frankly regulatory environment in specific countries do change. And we'd like to maintain that optionality to choose the specific sites and even the specific countries out of a few that we're working with. Speaker 200:21:14At the latest point that wouldn't impact our schedule. Speaker 700:21:21Great. And then just a follow-up on the cadaveric testing results from the refinements that you're going to put in play. Is there an are there more cadaver lab sessions that are required before you kind of get to that fully integrated, I guess, era and move forward with the pre VNB testing? Thanks. Taking all the questions. Speaker 200:21:46Yes. So the answer to that is certainly yes. We're well on the way to implementing a lot of these refinements already And they're being primarily implemented into this next build, which will then be tested through robust cadaveric testing as well as a number of other tests. Speaker 700:22:12Great. Thank you. Operator00:22:16Ladies and gentlemen, this concludes our Q and A and today's conference call. We'd like to thank you for your participation. You may now disconnect your lines.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallVicarious Surgical Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vicarious Surgical Earnings HeadlinesVicarious Surgical (NYSE:RBOT) Trading Up 20% - Here's WhyApril 25, 2025 | americanbankingnews.comVicarious Surgical Receives Continued Listing Standard Notice from the NYSEApril 11, 2025 | gurufocus.comShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.May 5, 2025 | Timothy Sykes (Ad)Vicarious Surgical Receives Continued Listing Standard Notice from the NYSEApril 11, 2025 | businesswire.comVicarious Surgical Announces President Transition to Board Member RoleMarch 24, 2025 | businesswire.comVicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 18, 2025 | finance.yahoo.comSee More Vicarious Surgical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vicarious Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vicarious Surgical and other key companies, straight to your email. Email Address About Vicarious SurgicalVicarious Surgical (NYSE:RBOT). operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.View Vicarious Surgical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Upcoming Earnings American Electric Power (5/6/2025)Advanced Micro Devices (5/6/2025)Marriott International (5/6/2025)Constellation Energy (5/6/2025)Arista Networks (5/6/2025)Brookfield Asset Management (5/6/2025)Duke Energy (5/6/2025)Energy Transfer (5/6/2025)Mplx (5/6/2025)Ferrari (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 8 speakers on the call. Operator00:00:00Hello, and welcome to Vicarious Surgical's 2024 First Quarter Earnings Call. My name is Elliot, and I'll be coordinating your call today. I would now like to hand over to Caitlin Brosco, Head of Investor Relations. Operator00:00:18The floor is yours. Please go ahead. Speaker 100:00:21Thanks, Elliot, and thank you all for joining. With me today for prepared remarks are Adam Sacks, Co Founder and Chief Executive Officer and Bill Kelly, Chief Financial Officer. Later, Randy Clark, our new company President, will join for the Q and A portion of this call. Today after market closed, Bakery Surgical released financial results for the 3 months ended March 31, 2024. A copy of this press release is available on the company website. Speaker 100:00:48Before we begin, I'd like to remind you that management will make statements during this call that include forward looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward looking statements. All forward looking statements, including without limitation, those relating to obtaining approval for the Vicari Surgical System and timing for any such approval, our operating trends and future financial performance, expense management, market opportunity and commercialization are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that would cause actual results or events to materially differ from those anticipated or implied by these forward looking statements. Accordingly, you should not place any undue reliance on these statements. Speaker 100:01:44For a list and description of the risks and uncertainties associated with the business, please refer to the risk factors set forth in our Securities and Exchange Commission filings, including our most recent Form 10 ks and Form 10 Q. This conference call contains time sensitive information and is accurate only as of this live broadcast today, April 29, 2024. Vicarious Surgical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward looking statements, whether because of new information, future events or otherwise. Now, I'll hand the call over to Adam for prepared remarks. Speaker 200:02:22Thanks, Kate, and thank you, everyone, for joining us. I'm proud to report a strong start to the year as we advance our mission to improve lives by transforming surgical robotics. In the Q1, we made meaningful progress toward the finalization of our B1.0 system. The collective efforts of our development team culminated in the completion of our spring cadaver lab at the end of March. This lab marks the first use of our integrated D1.0 system in a catabaric procedural setting with the primary goal of validating the capabilities and potential of the new systems feature set. Speaker 200:02:58I'm pleased to share that the lab proceeded as we had anticipated, verifying several advancements in development and yielding valuable insights across the system. During the lab, our V1.0 system showcased the tremendous potential inherent in our novel platform, underpinned by the new fortified software, electronic and mechanical architecture and supported by enhanced instrumentation and visualization technology. The V1.0 system exhibited the dynamic motion capabilities of our patient cart, facilitated maneuverability within the abdominal cavity and enabled 360 degree visualization and access to targeted surgical sites. We highlighted many of these specific V1 point development goals in our remarks last year, and I'm happy to report the success of our team's diligent efforts since. As anticipated, in addition to our development success, the lab offers insight into the additional refinements required for our final system. Speaker 200:04:00Over the next few quarters, our team will focus on leveraging these insights to fine tune the V1.0 system in preparation for formal verification and validation against the broader landscape for surgical robotics to remind against the broader landscape for surgical robotics to remind our stakeholders why we believe our offering is poised to take a disproportionate share of this market over time. Even with considerable progress over the past few decades, the field of surgical robotics is still in its infancy. Despite substantial growth and various new market entrants, around 96% of the estimated $150,000,000,000 market opportunity remains white space. Recent strategic activity in the space continues to strongly support this notion that robotics is the future of surgery. And while existing robotic technology has notably augmented surgeons' capabilities, these multi port systems have amplified costs for the hospital system without addressing the technology's fundamental dexterity and range of motion constrain surgeons to utilizing wrist on a stick instrument that necessitate multiple incisions to the patient and require cumbersome instrument triangulation by the surgeon. Speaker 200:05:26This approach introduces complexity both during the procedure and in preoperative steps contributing to the steep learning curve for new users and the low 4% adoption rate for surgical robotics today. Vicarious Surgical was founded on the recognition of these limitations of multi port surgical robots. Instead of building off legacy robotic technology, we reimagined surgical robotics from the ground up. Core to our reimagined architecture is our proprietary decoupled actuator technology, which prevents the force buildup in the joints of each instrument arm, significantly enhancing the dexterity and range of motion of our system and thereby eliminating the need for multiple incisions required for instrument triangulation. Through a single 18 millimeter incision, our system is designed to achieve full intra abdominal access with high force exertion for our targeted surgical indication. Speaker 200:06:25We believe this streamlined approach will enhance procedural efficiency and remove the training demand on new surgeons for every procedure. With today's offerings predominantly limited to multi port wrist on a stick technology, we along with our hospital system partners see this as a distinct clinical and commercial advantage. We are confident that our technology's unique capabilities will establish a lasting competitive edge for us in the robotic assisted surgery market. And with the completion of our spring cadaver lab, we are excited to have taken another step towards finalizing our differentiated system. With that, I will turn it over to Bill to review our financial performance. Speaker 300:07:09Thank you, Adam. As expected, our 2023 initiatives streamline resources, optimize spending and restructure the company for maximum efficiency are yielding a benefit to our 2024 expense profile. As a result, total operating expenses for the Q1 of 2024 were $16,100,000 28% decrease compared to $22,300,000 in the Q1 of last year. R and D expenses for the Q1 of 2024 were $10,000,000 compared to $13,400,000 in the Q1 of 2023. General and administrative expenses for the Q1 of 2024 were $5,000,000 down from $7,000,000 in the Q1 of 2023. Speaker 300:07:56In Q1 2024, sales and marketing expenses were $1,100,000 versus $2,000,000 in the Q1 of 2023. Again, the year over year reduction in operating expenses reflects the diligent efforts made throughout last year to optimize our burn and prioritize capital efficiency. Continuing on, adjusted net loss for the first quarter 2024 was $15,100,000 equating to a net loss of $0.09 per share as compared to an adjusted net loss of $20,800,000 or $0.17 per share in the Q1 of 2023. GAAP net loss for the Q1 of 2024 was $17,000,000 equating to a net loss of $0.10 per share, and this compares to a net loss of $26,900,000 or $0.21 per share in the Q1 of 2023. For a reconciliation of all non GAAP measures to GAAP, please review our earnings press release. Speaker 300:09:00We ended the Q1 of this year with approximately $84,000,000 of cash, cash equivalents and short term investments on our balance sheet. This represents a Q1 cash burn rate of approximately $14,000,000 Note that while Q1 cash burn was slightly elevated as a result of a few seasonally timed payments, we continue to expect full year 2024 cash burn to be approximately $50,000,000 and remain committed to disciplined capital allocation. 2024 is off to a strong start and our team is executing with the urgency and discipline needed to achieve our development timelines, including the completion of the V1.0 system build and integration this fall. We look forward to updating you as we progress with our business initiatives in the coming quarters. And with that, I'll turn the call back to Adam for closing remarks. Speaker 300:09:53Adam? Speaker 200:09:53Thank you, Bill. I'd like to close by reemphasizing the way in which we as a company have differentiated ourselves within the broader robotics market. While many surgical robotics companies continue to iterate on legacy platforms, we are taking a new path forward. While this approach takes careful time and consideration, we remain steadfast in the value of our unique technology. I'd like to thank all of our stakeholders, particularly our employees for their continued support of our mission and vision. Speaker 200:10:29Elliot, we're now happy to take any questions. Operator00:10:33Thank First question comes from Ryan Zimmerman with BTIG. Your line is open. Please go ahead. Speaker 400:10:55Thanks. Thanks for taking my questions. Good afternoon. Just maybe a few for me. Your R and D expenses came in a little higher, SG and A was certainly lower than I think we expected. Speaker 400:11:08But overall, really good expense management this quarter. Just kind of help us understand kind of how you're balancing the needs on kind of both sides of that P and L as you think about your progress and kind of what you have planned for the balance of this year? Speaker 300:11:24Great question. Obviously, as we've made a number of cost reductions year over year, the focus has really been on building a quality robot and getting it to market as fast as possible and such really where we try and draw the line there to focus and prioritize spending there. As noted in the call, our burn rate was probably a little bit higher than otherwise the run rate would be. That was really due to the seasonality of certain spending. As you can imagine, certain material expenses and things like that, they happen in one period versus another. Speaker 300:11:56That's why you're seeing that. But we still remain committed to $50,000,000 cash burn for the year. Speaker 400:12:03Okay. And then correct me if I'm wrong here, Adam, but the V1.0 wraps up in the fall of this year. Talk to us about kind of next steps from there, how that dovetails into potentially the establishment of a clinical trial, I think slated for maybe mid to late 2025, if I'm not mistaken, and kind of what you need to do once we get all the design and testing done for V1.0? Speaker 200:12:37Yes. I think that's a really important question. So as we finalize our V1.0 system and go into more sort of preliminary verification and validation testing, We're going to then roll that into all of the formal testing that's required. As I'm sure you'll recall, we're focused primarily on outside the U. S. Speaker 200:12:58Data collection in our clinical trial. And one of the advantages of that is in the verification and validation process, we need to do primarily the all of the essential performance and safety testing rather than all verification and validation testing. So once essential performance and safety testing is complete for our system, we'll then be able to start up our clinical trial in 2025. Speaker 400:13:27Thank you. Operator00:13:32We now turn to Adam Maeder with Piper Sandler. Your line is open. Please go ahead. Speaker 500:13:38Hi, Adam, Bill, Randy. Thank you for taking the questions and congrats on the progress. I wanted to start with the spring cadaver lab experience and just ask a little bit more color there. So I guess the first question would be multipart here. How many cadavers were performed? Speaker 500:13:57Who is doing the procedure? Was it surgeons that you guys partner with, talk about kind of setting a care. And then just bigger picture, maybe just what were the learnings from the Spring Cadaver lab? What went better than planned? And what were some of the challenges, if any, that may have arisen? Speaker 500:14:18And then I had a follow-up. Thanks. Speaker 200:14:22Yes. Super fair question. So overall, it was the very first cadaver that we performed. This was a single cadaver and will be the first of a number that we do over the course of this year. Overall, the procedure was designed to really test out the core functionality of our system and burn down and evaluate any potential issues and risks with it as early as possible, which is one of the reasons that we did it frankly on the earlier side of the spring. Speaker 200:14:59It was done by internal surgeons and surgeon partners and with a collaboration between 2 physicians. And overall, there were a number of things across frankly each subsystem that came up that we needed to focus on revising over the next 2 to 3 quarters. And that is why we've scheduled in this time over the next couple of quarters to make those revisions before we actually lock our V1.0 system. Speaker 500:15:35Yes. That's good color, Adam. And sorry to press here a little bit, but just to the extent that you're willing to share, I think you called it additional refinements in the prepared remarks to the final system. What are some of those things that you guys need to kind of smooth out before you go into final system integration in the fall? Speaker 200:16:02Yes. I'll give you a few examples of a few different things. So within the software, there were a handful of bugs that we encountered, including one on firmware within the arms and the sensing of the arms that caused some challenges along the way. That one has actually already been resolved. A few small things between interaction between the lubrication of the trocar seal and the arm itself and the sensing of the arm. Speaker 200:16:35Just to name, I'd say 2 out of frankly a decent handful of similar things. So either one of the 2 of those are fairly easy to resolve. It's just that there are a number that we need to tackle and that's why we want to give ourselves a couple of quarters to do that and to really heavily test out the implementation of each solution. Speaker 500:17:02Yes. That makes sense to me. Thank you for that. And then just one last one, if I may. Maybe for Randy, and congratulations on the new role, by the way. Speaker 500:17:12I wanted to ask, you've been in the seat now for a few months. Maybe just talk about some of the early impressions from your vantage point of the company and the technology and how will you look to put your fingerprints on the broader organization going forward? Thanks again for taking the questions. Speaker 600:17:31Yes. No, I appreciate the new person question, Adam. So, as you mentioned, since joining at the end of January, I've really just been fully immersing myself into the intricacies of our business and really trying to familiarize myself with each team and taking deep dives into all aspects of our operations as you can imagine. And I can tell you, it's been an incredibly exciting journey so far, especially where you're going with Adam. I had the privilege of observing the team's unwavering dedication and hard work and commitment that led up to our spring Kadara lab. Speaker 600:18:07And that's one of my first takeaways that I want to double down on is just the talent that we have here at Vicarious Surgical is absolutely incredible, let alone the work ethic and commitments from the teams to really drive towards our mission. And I'm just focusing right now and being very committed to disciplined execution of our current objectives and consistently achieving our milestones. That's going to be key to ensuring our success in the long run. Speaker 500:18:38Thank Operator00:18:41you. We now turn to Josh Jennings with TD Cowen. Your line is open. Please go ahead. Speaker 700:18:54Hi, good afternoon. Thanks a lot for taking the questions. Wanted to just get an update on the plans for the OUS clinical trial to support the de novo submission. Any I know it's only been 2 months since the last call and the last update and less than that since our healthcare conference, but any further communications with the FDA on that trial design? And just I guess the second part of the question is thinking about international sites and how do you go about I know we're not till next year, but how do you go about establishing those relationships or maybe they're already in hand in terms of finding investigator sites and finding the right ones and developing those surgeon relationships or center relationships with Vicarious? Speaker 200:19:42Yes. Thanks, Josh. And 2 great questions there. So I'll start with the FDA side. So nothing that we have to share on that front directly. Speaker 200:19:52But what I will say is, as we're seeing the broader robotics base continue to develop, we are seeing other filings and frankly other approvals come through, many of which are occurring with entirely outside the U. S. Data as well as with about 30 patients each in each trial. So this is further confirming that unsurprisingly the guidance and support that the FDA is giving to us is being given in exactly the same way to the other new entrants in the space and they are following through on their commitments there. So that is very reassuring for us to see. Speaker 200:20:36As far as specific site selection and country selection, we are in conversations with a number of different locations. We do have time, but we are well on the way to working through this already. And one of the goals here is to maintain optionality for as long as we can. We actually view that as a distinct advantage, especially when frankly regulatory environment in specific countries do change. And we'd like to maintain that optionality to choose the specific sites and even the specific countries out of a few that we're working with. Speaker 200:21:14At the latest point that wouldn't impact our schedule. Speaker 700:21:21Great. And then just a follow-up on the cadaveric testing results from the refinements that you're going to put in play. Is there an are there more cadaver lab sessions that are required before you kind of get to that fully integrated, I guess, era and move forward with the pre VNB testing? Thanks. Taking all the questions. Speaker 200:21:46Yes. So the answer to that is certainly yes. We're well on the way to implementing a lot of these refinements already And they're being primarily implemented into this next build, which will then be tested through robust cadaveric testing as well as a number of other tests. Speaker 700:22:12Great. Thank you. Operator00:22:16Ladies and gentlemen, this concludes our Q and A and today's conference call. We'd like to thank you for your participation. You may now disconnect your lines.Read morePowered by